Insulet Co. (NASDAQ:PODD) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC cut its holdings in shares of Insulet Co. (NASDAQ:PODD) by 2.9% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 3,481 shares of the medical instruments supplier’s stock after selling 104 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Insulet were worth $755,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. William Blair Investment Management LLC raised its holdings in shares of Insulet by 145.1% in the 3rd quarter. William Blair Investment Management LLC now owns 732,923 shares of the medical instruments supplier’s stock valued at $116,894,000 after purchasing an additional 433,884 shares in the last quarter. Qube Research & Technologies Ltd raised its holdings in shares of Insulet by 227.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 386,687 shares of the medical instruments supplier’s stock valued at $61,673,000 after purchasing an additional 268,553 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in shares of Insulet by 62.4% in the 3rd quarter. Westfield Capital Management Co. LP now owns 637,261 shares of the medical instruments supplier’s stock valued at $101,637,000 after purchasing an additional 244,922 shares in the last quarter. Artisan Partners Limited Partnership acquired a new stake in shares of Insulet in the 3rd quarter valued at $29,455,000. Finally, Ownership Capital B.V. raised its holdings in shares of Insulet by 91.3% in the 3rd quarter. Ownership Capital B.V. now owns 287,132 shares of the medical instruments supplier’s stock valued at $45,795,000 after purchasing an additional 137,034 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on PODD. Piper Sandler reduced their price objective on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. JPMorgan Chase & Co. raised their price objective on shares of Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. Barclays reduced their price objective on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a report on Monday, February 26th. Finally, Stifel Nicolaus lifted their price target on shares of Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research note on Monday, February 5th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $243.21.

Insulet Trading Down 0.0 %

Shares of Insulet stock opened at $167.25 on Thursday. Insulet Co. has a 1 year low of $125.82 and a 1 year high of $335.91. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. The company has a market capitalization of $11.71 billion, a P/E ratio of 57.47, a PEG ratio of 2.96 and a beta of 0.98. The company’s fifty day moving average is $172.53 and its two-hundred day moving average is $179.35.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The company had revenue of $509.80 million for the quarter, compared to the consensus estimate of $461.26 million. During the same period last year, the firm posted $0.55 EPS. Insulet’s revenue for the quarter was up 37.9% on a year-over-year basis. Analysts forecast that Insulet Co. will post 3.08 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Shacey Petrovic sold 11,609 shares of Insulet stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total value of $1,891,338.28. Following the sale, the director now owns 2,567 shares of the company’s stock, valued at $418,215.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.80% of the stock is currently owned by insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.